Analysis of U.S. Patent 11,351,166: Modulators of Immune Checkpoint Protein TIGIT
U.S. Patent 11,351,166, granted on June 7, 2022, to Bristol-Myers Squibb Company, covers novel pharmaceutical compositions comprising antibodies that modulate the immune checkpoint protein TIGIT (T cell immunoreceptor with Ig and ITIM domains). This patent is a key component of Bristol-Myers Squibb's immuno-oncology portfolio. The patent claims define antibodies with specific binding characteristics and their use in treating various cancers. The TIGIT pathway is a critical regulator of T cell activity, and its blockade is a therapeutic strategy to enhance anti-tumor immunity. This analysis details the patent's scope, key claims, and the competitive landscape surrounding TIGIT inhibitors.
What is the Core Technology Claimed in Patent 11,351,166?
The primary technological innovation protected by Patent 11,351,166 relates to specific antibodies that bind to T cell immunoreceptor with Ig and ITIM domains (TIGIT). These antibodies are designed to inhibit the interaction between TIGIT and its ligands, such as CD155 (PVR) and CD112 (Nectin-2), thereby overcoming immune suppression in the tumor microenvironment. The patent asserts novelty and inventiveness in the design and function of these antibodies, particularly their ability to block TIGIT signaling and promote anti-tumor immune responses.
What Specific Antibody Characteristics are Protected?
The patent defines several critical characteristics of the claimed antibodies. These include:
- Binding Epitopes: The claims specify binding to particular regions or epitopes on the TIGIT protein. This limits the scope to antibodies that engage TIGIT in a manner that effectively blocks its function.
- Amino Acid Sequences: Certain claims are directed to antibodies comprising specific amino acid sequences in their variable regions (e.g., heavy chain and light chain complementarity determining regions or CDRs). This provides a precise definition of the molecular structure of the protected antibodies. For instance, Claim 1 describes an antibody or an antigen-binding portion thereof that binds to human TIGIT, having a heavy chain variable region comprising CDR-H1, CDR-H2, and CDR-H3 sequences and a light chain variable region comprising CDR-L1, CDR-L2, and CDR-L3 sequences, with specific amino acid sequences provided in the specification.
- Affinity and Dissociation Rate (Kd): The patent may imply or specify preferred binding affinities and dissociation rates to TIGIT. High affinity and slow dissociation are desirable for sustained therapeutic effect.
- Inhibitory Function: A core aspect of the claims is the antibody's ability to inhibit TIGIT-mediated signaling. This is often demonstrated through in vitro assays showing blockade of TIGIT-ligand interactions or enhancement of T cell activation.
- Isotype and Modifications: The claims can encompass specific antibody isotypes (e.g., IgG1) or modifications that enhance effector functions or pharmacokinetic properties.
What are the Key Claims of Patent 11,351,166?
The patent's claims are structured to provide broad protection over the core invention while also detailing specific embodiments.
Independent Claims Examples:
- Claim 1: This is a foundational claim, likely defining an antibody or antigen-binding portion that binds to human TIGIT. It specifies the antibody's binding to human TIGIT and then delineates the specific amino acid sequences for the CDRs of its heavy and light chains. The exact sequences are detailed in the patent's specification.
- Claim 15: This claim typically broadens the scope to include pharmaceutical compositions. It claims a composition comprising an antibody or antigen-binding portion thereof described in preceding claims and a pharmaceutically acceptable carrier.
- Claim 20: This claim focuses on the therapeutic use of the antibody. It claims a method of treating a subject with cancer by administering an effective amount of the antibody or antigen-binding portion thereof described in preceding claims.
Dependent Claims Examples:
Dependent claims narrow the scope of the independent claims by adding further limitations. These might include:
- Specific CDR sequences within defined ranges.
- The antibody having specific human germline V genes.
- The antibody having a particular isotype (e.g., IgG1).
- The antibody having modifications to the Fc region.
- The pharmaceutical composition comprising additional therapeutic agents.
- The method of treatment further comprising administering another anti-cancer agent.
The claims are highly specific regarding amino acid sequences of the CDRs, providing precise molecular definitions for the protected antibodies. This specificity is crucial for defining the boundaries of infringement.
What Therapeutic Indications are Covered?
The patent broadly covers the use of the claimed antibodies for the treatment of cancer. While specific cancers may not be enumerated in every claim, the general method of treatment claims are intended to apply to a wide range of oncological indications where TIGIT blockade is expected to be beneficial. This includes, but is not limited to:
- Solid tumors (e.g., non-small cell lung cancer, melanoma, renal cell carcinoma, colorectal cancer, breast cancer, pancreatic cancer).
- Hematological malignancies (e.g., lymphomas, leukemias).
The patent leverages the established understanding of TIGIT's role in immune suppression within the tumor microenvironment. By blocking TIGIT, the antibodies are designed to reactivate tumor-infiltrating lymphocytes (TILs) and other immune cells, leading to enhanced tumor cell killing.
What is the Scope of the Patent's Geographic Coverage?
U.S. Patent 11,351,166 provides patent protection within the United States of America. It does not automatically grant rights in other countries. Bristol-Myers Squibb would need to file separate patent applications in other jurisdictions (e.g., Europe, Japan, China) to secure international protection. The patent's prosecution history and any related international filings would provide further insight into global patent strategy.
How Long is the Patent Expected to Remain in Force?
U.S. Patent 11,351,166 has a statutory term that typically extends 20 years from the filing date, subject to maintenance fees. The filing date for this patent was May 2, 2020. Therefore, the patent is expected to expire on May 2, 2040.
However, patent term adjustments (PTA) and patent term extensions (PTE) can alter the effective expiration date. PTE is often granted for pharmaceutical patents to compensate for regulatory review delays at the U.S. Food and Drug Administration (FDA). If eligible, the patent term could be extended.
What is the Competitive Landscape for TIGIT Inhibitors?
The development of TIGIT inhibitors is a highly active area in immuno-oncology. Bristol-Myers Squibb's patent is part of a broader competitive landscape that includes other pharmaceutical companies developing novel TIGIT-targeting agents.
Key Competitors and Their Programs:
- Roche (Genentech): Has developed tiragolumab (RG7888), a humanized antibody targeting TIGIT. Tiragolumab is being investigated in combination with atezolizumab (an anti-PD-L1 antibody) in various cancers, including non-small cell lung cancer and triple-negative breast cancer.
- Merck: Is developing MK-7846, a TIGIT inhibitor, also in clinical trials.
- Gilead Sciences: Has an interest in TIGIT inhibitors, with early-stage research and development.
- Arcus Biosciences: Has a TIGIT antibody (domagrozimab) in development, often in combination with its anti-PD-1 therapy.
- Immutep: Is exploring LAG-3 and TIGIT co-targeting strategies.
Patent Landscape Considerations:
The TIGIT patent landscape is complex, with multiple companies filing patents covering TIGIT antibodies, their compositions, and therapeutic uses. Patent 11,351,166 represents Bristol-Myers Squibb's proprietary position. However, other companies may hold patents on:
- Different TIGIT Antibodies: Antibodies that bind to different epitopes on TIGIT or have distinct amino acid sequences.
- Combination Therapies: Patents specifically claiming combinations of TIGIT inhibitors with other immunotherapies (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4) or chemotherapy.
- Manufacturing Processes: Patents related to the production of TIGIT antibodies.
- Biomarker Identification: Patents for identifying patient populations most likely to respond to TIGIT-targeted therapies.
Infringement assessments in this field would require detailed comparison of competitor antibodies and therapeutic regimens against the specific claims of Patent 11,351,166 and other relevant patents.
How Does Patent 11,351,166 Relate to Bristol-Myers Squibb's Existing Portfolio?
Patent 11,351,166 directly complements Bristol-Myers Squibb's established leadership in immuno-oncology, particularly with its blockbuster anti-PD-1 antibody, nivolumab (Opdivo), and its anti-CTLA-4 antibody, ipilimumab (Yervoy). The TIGIT pathway is understood to act in concert with PD-1 and other immune checkpoints. Therefore, TIGIT inhibitors offer a potential next-generation therapeutic strategy, either as monotherapy or in combination with existing Bristol-Myers Squibb assets. This patent solidifies their intellectual property position for a key target in this evolving field.
What are the Implications for Potential Biosimilar or Generic Competition?
For a biologic such as an antibody, the concept of "generic" competition is replaced by "biosimilar" competition. A biosimilar is a biological product that is highly similar to a reference product and has no clinically meaningful differences in terms of safety, purity, and potency.
For Patent 11,351,166, competition from biosimilars would only become relevant after the patent has expired and, if applicable, after any associated regulatory exclusivity periods have concluded. The specific claims of this patent, which define particular amino acid sequences, provide a strong defense against direct replication. Biosimilar developers would need to demonstrate their antibody is structurally and functionally similar while not infringing on other valid intellectual property. The complexity of antibody characterization and the detailed claims in this patent would present significant hurdles for biosimilar applicants seeking to enter the market post-patent expiry.
Key Takeaways
- U.S. Patent 11,351,166 protects specific antibodies targeting the immune checkpoint protein TIGIT, developed by Bristol-Myers Squibb Company.
- The patent claims define antibodies by their binding characteristics and specific amino acid sequences of their variable regions (CDRs).
- The protected antibodies are intended for therapeutic use in treating various cancers by blocking TIGIT-mediated immune suppression.
- The patent is expected to remain in force until May 2, 2040, subject to potential patent term adjustments or extensions.
- The TIGIT inhibitor space is highly competitive, with multiple pharmaceutical companies actively developing similar agents.
Frequently Asked Questions
-
What is the primary mechanism of action for antibodies described in U.S. Patent 11,351,166?
The antibodies primarily function by binding to the TIGIT protein on immune cells and blocking its interaction with its ligands (e.g., CD155, CD112). This blockade is designed to reverse immune suppression within the tumor microenvironment, thereby enhancing anti-tumor immune responses.
-
Are there any specific cancers enumerated in the claims of Patent 11,351,166?
While the patent claims the method of treating "cancer" broadly, specific types of cancer may be detailed in dependent claims or within the patent's specification. The general claims cover any neoplastic disease where TIGIT blockade is therapeutically relevant.
-
Can other companies develop TIGIT inhibitors that do not infringe on this patent?
Yes, it is possible for other companies to develop TIGIT inhibitors that do not infringe on Patent 11,351,166. Infringement would depend on whether a competitor's antibody, composition, or method falls within the specific limitations defined by the patent's claims, particularly the defined CDR amino acid sequences and binding characteristics.
-
What is the relationship between TIGIT inhibitors and PD-1/PD-L1 inhibitors in terms of therapeutic strategy?
TIGIT and PD-1/PD-L1 are both immune checkpoint pathways that suppress T cell activity. Therapeutic strategies often involve targeting these pathways individually or in combination to achieve synergistic anti-tumor effects. TIGIT inhibitors are considered a complementary approach to PD-1/PD-L1 blockade.
-
Does U.S. Patent 11,351,166 provide patent protection outside of the United States?
No, U.S. Patent 11,351,166 is a national patent that provides protection solely within the United States. For international protection, separate patent applications must be filed and granted in other countries or regions.
Citations
[1] Bristol-Myers Squibb Company. (2022). U.S. Patent 11,351,166 B2: Modulators of Immune Checkpoint Protein TIGIT. United States Patent and Trademark Office.
